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Abstract
Background: Alterations in serum and membrane lipids may be involved in schizophrenia pathophysiology. It is
not known whether lipid profiles are associated with disease severity or current symptom level.
Methods: Clinical and lipid data were gathered from 55 patients with schizophrenia admitted to psychiatric
emergency wards in an acute stage of the disease (T1). The patients were re-examined after 5 years at a stable
phase (T2). The clinical assessments included Positive and Negative Syndrome Scale (PANSS total, positive, negative)
and Global Assessment of Functioning (GAF S, symptom and F, function). Serum lipids (cholesterol and triglyceride)
and membrane polyunsaturated fatty acids (PUFA, LCPUFA) were measured. Healthy controls were recruited among
hospital workers.
Results: Serum triglyceride was significantly higher in patients with schizophrenia compared to healthy controls
both at T1 and T2 (p < 0.001), while serum cholesterol did not differ significantly. The levels of serum lipids in
patients remained stable over time. At T1, serum lipids and symptoms were not significantly correlated. At T2,
higher serum lipids were associated with more severe symptoms and poorer functioning. Higher serum lipid levels
at T1 were associated with more severe symptoms and poorer functioning at T2; cholesterol with GAF-S (p < 0.05),
triglyceride with PANSS total (p < 0.05), GAF-S (p < 0.01) and GAF-F (p < 0.01). Membrane lipids were significantly
lower in the patient group compared to healthy controls at T1 (PUFA p < 0.001, LCPUFA p < 0.001), but not at T2.
Membrane lipids were not significantly correlated with symptoms at T1, but significantly associated with negative
symptoms and functioning at T2 as previously reported.
Conclusions: The present findings suggest different roles of membrane and serum lipids in schizophrenia
pathophysiology. To further elucidate the relation of lipid biology to disease traits, replication in independent
studies of longitudinal samples are warranted.
Abbreviations: ARA, Arachidonic acid; DHA, Docosahexaenoic acid; EPA, Eicosapentaenoic acid; GAF, Global
assessment of functioning; LCPUFA, Long chain polyunsaturated fatty acids, omega-3 + omega-6, with 20 or more
carbon atoms, in red blood cells; MINI, Mini international neuropsychiatric interview; PANSS, Positive and negative
syndrome scale; PUFA, Polyunsaturated fatty acids, omega-3 +, omega-6 polyunsaturated fatty acids in red blood
cells; RBC, Red blood cells; SCID, Structural clinical interview for DSM-IV
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Background
Abnormal lipid biology may play a significant role in the
pathophysiology of schizophrenia. Most studies show
that patients with schizophrenia have higher levels of
serum lipids (cholesterol and triglyceride) than a healthy
population [1, 2]. This dyslipidemia has been regarded
as a result of antipsychotic medication and lifestyle fac-
tors [3], but dyslipidemia has also been demonstrated in
unmedicated schizophrenia patients [4–7]. Altered me-
tabolism of membrane lipids (polyunsaturated fatty
acids, PUFA) is another aspect of lipid biology suggested
to be involved in schizophrenia pathophysiology [8].
Lower levels of PUFA in cell membranes have been
found in schizophrenia [9, 10], both in the acute and
chronic stage of the disease [11].
The course and outcome of schizophrenia is regarded
as heterogeneous. The nature of the relation between
lipid profiles, lipid metabolism and clinical characteris-
tics of schizophrenia is mainly unknown. Particularly, it
is not known whether lipid profiles are associated with
the disease itself, and / or current symptoms. Conflicting
findings of associations between lipid levels and symp-
tom severity may represent fluctuations of lipid levels as
the disease progresses [12, 13]. It is possible that lipid
levels are stable while symptoms, especially positive
psychotic symptoms, fluctuate during the course of the
disease. The presence of abnormal lipid metabolism
from the onset of the disease that remains stable inde-
pendent of disease symptoms and antipsychotic treat-
ment, may suggest that lipid abnormalities are a disease
trait, and thus involved in the pathophysiological devel-
opment of the disease, as suggested for cholesterol [14].
Lipids that are aberrant during an acute psychotic epi-
sode of schizophrenia and normalized after the acute
episode may indicate a role for lipids in relation to dis-
ease symptoms, which has been suggested for membrane
lipids (PUFA) [15]. The role of lipid biology in relation
to disease symptoms can best be investigated in a longi-
tudinal study, following patients during different stages
of the disease.
Several lines of evidence suggest that the pathophysi-
ology of schizophrenia involves immune- and inflamma-
tory pathways, integrated with redox-regulation [16, 17].
It has been suggested that the composition of membrane
lipids is abnormal [18, 19], potentially due to disturbed
redox-regulation [20, 21]. Oxidative stress can also affect
serum lipids and cause dyslipidemia [22–24]. In schizo-
phrenia, levels of both serum- and membrane lipids
seem aberrant [9, 25, 26] Thus, an alteration in redox-
regulation can be a common factor linking abnormalities
of both serum and membrane lipids in schizophrenia. A
change in membrane lipid composition in neuronal cells
can affect neurotransmission, symptoms and behavior in
schizophrenia [27]. Both serum and membrane lipids
have been found to predict the outcome of treatment
[28, 29]. We hypothesize that both serum lipid and
membrane lipid alterations may be involved in the
pathophysiology of schizophrenia.
We have reported earlier that symptom levels were
positively associated with two types of lipids, both serum
lipids and membrane lipids in patients with schizophre-
nia [26]. How these relationships change over time is
unknown. Here we investigate with a longitudinal de-
sign, using a sample with repeated assessment, if the
lipid profiles vary in relation to clinical characteristics;
positive and negative symptoms (PANSS) and general
symptoms and functioning (GAF). We hypothesize that
there is a core abnormality in both membrane and
serum lipid systems in schizophrenia, reflected in
abnormal membrane and serum lipid levels, and this is
independent of disease phase. In order to test this hy-
pothesis, we examined a group of patients and healthy
controls at baseline and after 5 years follow-up.
The aims of the current study are first to determine if
there are differences in lipid profiles (serum lipids and
membrane lipids) between people with schizophrenia
and healthy controls and if they are stable over a 5 years
period. The second aim is to explore the relationship be-
tween lipid profiles and clinical characteristics during
the course of schizophrenia. We measured the levels of
serum and membrane lipids at admission to emergency
psychiatric wards and after 5 years follow-up in out-
patients clinics or at long-term care facilities, and their
association with the disease and clinical symptoms. Re-
peated measures of lipid levels during the course of
schizophrenia and their relationship with clinical symp-
toms may elucidate whether lipid profiles are associated
with stable disease characteristics (traits).
Methods
Participants
In a longitudinal study, socioeconomic, clinical and bio-
logical data were gathered from a group of 55 patients
with schizophrenia and schizoaffective disorders. The
patients were a sub-sample of a group of 99 patients
participating in a trial of an omega-3 fatty acid and anti-
oxidants in schizophrenia [30]. The patients were re-
cruited when admitted to psychiatric emergency wards
in southern Norway in 2001 to 2003 (T1) [30]. They
were examined again between 2006 and 2010 (T2), with
a mean follow-up time of 61 months. Of the 44 patients
not included in the follow-up study, 21 did not wish to
participate, twelve were not located, nine were dead, and
two had moved to other regions of Norway. The sub-
sample of 55 patients did not statistically differ from the
main sample of 99 patients with regard to demographics
or main outcome variables at T1. When examined at the
inclusion (T1), the patients were admitted to an
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emergency psychiatric ward and thus considered in an
acute stage of the disease. Five years later (T2), the pa-
tients were treated at out-patient clinics or at psychiatric
long term care facilities, and considered to be in a more
stable chronic stage. The patients were screened for
somatic illness at inclusion and at follow-up. The data
from an overlapping sample at T2 have been presented
earlier [26]. In addition, healthy controls were recruited
among hospital employees from the same age group as
patients. At T1, 20 healthy controls were included. At
T2, 51 healthy controls were examined. Of these, 16 were
a subsample from T1, and an additional 35 healthy par-
ticipants were included as healthy controls at T2. To be
included as healthy controls, participants and their first-
degree relatives could not have any ongoing or past se-
vere psychiatric disorder. This was determined with an
interview assessing severe mental illness, and screening
for ongoing and past psychiatric disorder using the Mini
International Neuropsychiatric Interview (MINI). In
addition, their physical health was assessed with self-
report and short screening interview addressing current
or history of somatic illness in the healthy control
participants.
Demographics of patients and healthy controls are re-
ported in Table 1. The study was approved by the Re-
gional Committee for Medical Research Ethics. All
participants gave written informed consent. Inclusion of
patients ended in June of 2010 and results were submit-
ted in 2015. This delay was partly caused by techno-
logical difficulties which led to re-analyzes and data
analysis could not start until late 2011, and partly due to
clinical duties for the first author.
Clinical assessment
All patients were diagnosed with the Structural Clinical
Interview for DSM-IV (SCID). To measure the severity
of symptoms the Positive and Negative Syndrome Scale
Structured Interview Version (SCI-PANSS), and Global
Assessment of Functioning (GAF) were used. In addition
to PANSS total, we reported positive and negative
PANSS components from a model established by van
der Gaag et al. [31]. The split version of GAF was used,
which includes Symptom (GAF-S) and Functioning
(GAF-F) scales [32]. At T1 the patients were assessed by
a group of 16 investigators from the participating hospi-
tals. DKS was among the investigators at T1, who under-
went trainings sessions and the interrater reliability was
assessed by rating ten (median) videotaped interviews
[33]. At T2, all patients were assessed by the same clin-
ical investigator (DKS).
Biochemical assays
Blood for lipid analyses was sampled after overnight fast-
ing. Serum lipids and membrane lipids were measured.
At T1 serum lipids were not obtained from healthy
controls.
Serum lipids (cholesterol and triglyceride) were ana-
lyzed at the Department of Clinical Chemistry at Aker
Hospital (T1) and Diakonhjemmet Hospital (T2) with
standard enzymatic methods from Roche Diagnostics
Table 1 Demographics
Patients T1 Healthy controls T1 Patients T2 Healthy controls T2
n = 55 n = 20 n = 55 n = 51¤
Age 26.5 ± 6.1 31.1 ± 5.3 31.3 ± 5.7 33.0 ± 6.1
Sex (% male) 69.1 55.0 69.1 54.9
Smokers (%) 31 (56.4) 7 (35.0) 29 (52.7) 9 (17.6)
Primary school (%) a 14 (25.5) 3 (15.0) 9 (17.0) 1 (2.0)
Secondary school (%) 30 (54.5) 8 (40.0) 30 (56.6) 8 (16.0)
University / college (%) 11 (20.0) 9 (45.0) 14 (26.4) 41 (82.0)
PANSS total 81 (71,93) 82 (57,101)
PANSS negative 22 (16,27) 25 (18,31)
PANSS positive 17 (13,21) 16 (11,19)
GAF-S 35 (30,40) 45 (37,58)
GAF-F 37 (31,40) 47 (38,58)
PANSS positive and negative symptoms scale
PANSS total positive and negative symptoms scale
PANSS positive positive component: items P1 + P3 + P5 + P6 + G9
PANSS negative negative component: items N1 + N2 + N3 + N4 + N6 + G7 + G8 + G16
GAF global assessment of functioning, S symptoms, F functioning
Age mean ± standard deviation
PANSS, GAF: median (25,75 percentiles)
a data missing from patient T2 n = 2, control T2 = 1
¤ 16 healthy controls from T1, 35 additional healthy controls included at T2
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Norge AS, Oslo, Norway. For analyses of polyunsatur-
ated fatty acids washed blood cells were stored at−70 °C
and sent within 3 months in dry ice to Mylnefield Re-
search Services LTD, Dundee, United Kingdom, who did
the analysis. The lipids were extracted, converted into
fatty acid methyl esters, and analyzed by gas chromatog-
raphy, yielding fatty acid profiles. In total 28 species of fatty
acids from C14:0 to C24:1 is reported as micrograms per
gram of RBC (red blood cells). The sum of omega-3 fatty
acids is C18:3 + C18:4 + C20:3 + C20:5 + C22:5 + C22:6. The
sum of omega-6 fatty acids is C18:2 + C18:3 + C20:2 +
C20:3 + C20:4 + C22:4 + C22:5. The sum of omega-3 and
omega-6 is named polyunsaturated fatty acids (PUFA). The
sum of PUFA with 20 or 22 carbon atoms is named long-
chain polyunsaturated fatty acids (LCPUFA).
Pharmacological treatment
Use of antipsychotic medication may affect the levels of
serum lipids. The current and previous use of antipsy-
chotics and other pharmacological agents in the patients
were registered from interviews and medical records in-
formation. At T2, detectable levels of antipsychotic drug
in serum samples were measured to control for adher-
ence (therapeutic drug monitoring). Use of medication
for dyslipidemia was registered.
Statistics
All statistical analyses were performed using SPSS ver-
sion 20 (SPSS Inc, Chicago, IL, USA / IBM, New York,
USA). Demographical and clinical variables are pre-
sented as average values or proportions. Parametric or
non-parametric tests were chosen depending on the dis-
tribution of variables. The Wilcoxon signed rank test
was used to compare lipid levels within patients. The
Mann–Whitney test was used to compare lipid levels be-
tween patients and healthy controls. Two-sided tests
were used, and the significance level was set to p < 0.05.
Spearman’s correlation coefficients (rs) were used to
evaluate the relationship between lipid data and clinical
symptoms (PANSS and GAF).
Results
Clinical characteristics
The patients had significantly lower GAF score at T1
than T2; GAF-S (p < 0.001) and GAF-F (p < 0.001), while
the PANSS scores were not significantly different be-
tween T1 and T2. See Table 1 for details.
Use of medication
No patients or healthy controls used medication for dys-
lipidemia. At T1 (admitted to an emergency psychiatric
ward) all 55 of the patients used antipsychotic medica-
tion, but only 26 (47.3 %) used antipsychotic medication




The levels of triglyceride were significantly higher in pa-
tients with schizophrenia than in healthy controls both
at T1 (p < 0.001), and at T2 (P < 0.001) (Table 2). The dif-
ference in cholesterol between patients (T1 and T2) and
healthy controls (T2) was not significant. Fasting serum
lipid data were not available in the healthy control group
at T1. The levels of serum lipids (triglyceride and choles-
terol) remained stable in the patient group over time,
with no significant difference between T1 and T2. In the
patient group, serum lipid levels remained stable over
the 5 year follow-up period, illustrated with significantly
correlated levels at T1 and T2 for both cholesterol (rs =
0.63, p < 0.001) and triglyceride (rs = 0.54, p < 0.001).
Membrane lipids
Membrane lipids were significantly lower in the patient
group compared to healthy controls at T1, both for
PUFA (p < 0.001) and LCPUFA (P < 0.001) (Table 2). At
Table 2 Serum and membrane lipids, patients and healthy controls, case–control and longitudinal data
Patients T1 Patients T2 Healthy controls T1 Healthy controls T2
n = 55 n = 55 n = 20 n = 51
PUFA 434 (171,507) 471 (440,513)*** 478 (446,495)*** 470.0 (437,508)
LCPUFA 283 (89,337) 308 (291,334)*** 307 (293,330)*** 306 (287,336)
S-cholesterol 5.00 ± 1.12 5.36 ± 1.20 ¤ 5.05 ± 0.84
S-triglyceride 1.50 (0.80,2.48)### 1.33 (0.95,2.66)### ¤ 0.85 (0.59,1.12)
***P <0.001 vs. patients T1,
### P < 0.001 vs. healthy controls T2
¤not measured
Serum cholesterol: normally distributed, mean ± standard deviation
Serum triglyceride, PUFA, LCPUFA: non-normally distributed, median (25,75 percentiles)
Patients T1 vs patients T2: Wilcoxon signed rank test
Patients T1 and T2 vs healthy controls T1: Mann–Whitney test
Healthy control T1 vs healthy controls T2: Wilcoxon signed rank test
PUFA = omega-3 + omega-6 polyunsaturated fatty acids in red blood cells
LCPUFA = omega-3 + omega-6 PUFA with 20 or more carbon atoms in red blood cells
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T2, there was no difference in the levels of membrane lipids
between patients and healthy controls. The patients with
schizophrenia had significantly lower levels of membrane
lipids at T1 than at T2, both for PUFA (p < 0.001) and
LCPUFA (p < 0.001) (Table 2). As reported earlier, the dis-
tribution of PUFA was bimodal at T1, defining a low and a
high PUFA group, and normal at T2 [9]. The mean levels of
membrane lipids increased only from T1 to T2 in patients
belonging to the low PUFA group at T1. PUFA levels at T1
and T2 were not significantly associated. For healthy con-
trols, there was no significant difference between mem-
brane lipid levels at T1 and T2.
Relationship between lipid levels and clinical characteristics
Serum lipids
In general, the associations between serum lipids and
symptoms and functioning were stronger at T2 than T1
(Table 3). There were no significant relationship between
the lipid levels and clinical variables at T1. As reported
earlier, there was a significant correlation between chol-
esterol and GAF-S at T2 (p = 0.02), and significant corre-
lations between triglyceride and GAF-S (p = 0.001),
GAF-F (p = 0.01) and PANSS positive (p = 0.04). The as-
sociations at T2 indicate that higher serum lipids were re-
lated to poorer functioning and more severe symptoms.
We also investigated associations between serum lipid
levels at T1, and symptom levels at T2. The results are
reported in Table 4. Triglyceride at T1 was significantly
correlated to PANSS total (p = 0.04), GAF-S (p = 0.003)
and GAF-F (p = 0.006) at T2. For cholesterol at T1 there
was significant correlation to GAF-S at T2 (p = 0.05). All
these associations indicate that higher serum lipids at T1
were related to poorer functioning and more severe
symptoms at T2.
Membrane lipids
As for serum lipids, the associations between membrane
lipids and symptoms and functioning were stronger at
T2 than T1 (Table 3). There were no significant relation-
ships between these lipids and clinical variables at T1. At
T2, there were significant correlations between LCPUFA
and PANSS negative (p = 0.001), PANSS total (p = 0.02),
GAF-S (p = 0.02) and GAF-F (p = 0.04). PUFA at T2 was
correlated to PANSS negative (p = 0.02). All associations
at T2 indicate that higher concentrations of membrane
lipids are linked to poorer functioning and more severe
symptoms. Analyses of relationship between membrane
lipid levels at T1 and symptom levels at T2 indicate no
significant associations.
Discussion
The main findings of the present study were repeated
higher levels of serum triglyceride in schizophrenia pa-
tients than in healthy controls during a 5 year period,
while membrane lipid levels (PUFA) were lower in the
acute stage of the disease (T1). There were no significant
associations between lipid levels and symptoms in the
acute stage (T1), while at the chronic stage (T2) both
serum and membrane lipid levels were associated with
Table 3 Association (rs) between lipid levels in serum and cell membranes and clinical characteristics in patients
S-triglyceride S-cholesterol RBC PUFA RBC LCPUFA
T1 T2 T1 T2 T1 T2 T1 T2
PANSS total 0.06 0.26 0.01 0.15 0.08 0.14 0.09 0.31*
PANSS negative 0.18 0.26 0.19 0.11 0.21 0.32* 0.20 0.52***
PANSS positive −0.04 0.28* −0.03 0.22 −0.02 0.01 −0.07 0.11
GAF-S 0.13 −0.48*** 0.26 −0.30* −0.24 −0.22 −0.26 −0.32*
GAF-F 0.07 −0.32* 0.24 −0.23 −0.19 −0.21 −0.23 −0.29*
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
Spearman’s correlation coefficient is reported
PANSS positive and negative syndrome scale
GAF global assessment of functioning, S symptoms, F functioning)
PANSS Positive positive component; items P1 + P3 + P5 + P6 + G9
PANSS Negative negative component; items N1 + N2 + N3 + N4 + N6 + G7 + G8 + G16
PUFA = omega-3 + omega- 6 polyunsaturated fatty acids in red blood cells (RBC)
LCPUFA = omega-3 + omega-6 PUFA with 20 or more carbon atoms in red blood cells (RBC)
Table 4 Association (rs) between serum lipid levels in serum at
T1 and clinical characteristics at T2
S-triglyceride T1 S-cholesterol T1
PANSS positive T2 0.21 0.06
PANSS negative T2 0.27 0.15
PANSS total T2 0.28* 0.11
GAF-S T2 −0.41** −0.28*
GAF-F T2 −0.39** −0.26
*0.01 ≤ P < 0.05, **P < 0.01
Spearman’s correlation coefficient is reported
There was no significant association between levels of PUFA (polyunsaturated
fatty acids) / LCPUFA (long chain polyunsaturated fatty acids) at T1 and
symptoms at T2
PANSS positive and negative syndrome scale
GAF global assessment of functioning, S symptoms, F functioning)
PANSS positive items P1 + P3 + P5 + P6 + G9
PANSS negative items N1 + N2 + N3 + N4 + N6 + G7 + G8 + G16
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symptoms and functioning. Higher serum lipid levels in
the acute stage (T1) were also associated with more severe
symptoms in the chronic stage (T2). These findings sug-
gest serum lipid abnormalities as a putative core disease
mechanism related to disease traits, while membrane
lipids seem to fluctuate in different disease phases. This
may be related to changes in neuroinflammatory and oxi-
dative processes which are reported to contribute to dis-
ease progression and underlie symptom severity [34, 35].
We found higher levels of serum triglyceride in the pa-
tient group both at an acute stage (T1) and at follow-up
5 years later (T2). In longitudinal studies, dyslipidemia in
patients with schizophrenia has primarily been studied
as a side effects of antipsychotic medication [36]. Some
studies have shown that dyslipidemia and other meta-
bolic risk factors may be present in early stages of the
disease, before treatment is initiated [37, 38]. Antipsy-
chotics have been shown to up-regulate the expression
of cholesterol transport proteins [39]. Further, the degree
of dyslipidemia may be predictive of the effect of treat-
ment [40]. In the present study, a large proportion of pa-
tients did not receive antipsychotic treatment when
lipids were measured (47 % at T1, 20 % at T2). Thus, the
sustained higher levels of serum triglyceride, suggest that
dyslipidemia may be associated with the disease itself,
and not only a result of medication. Further, smoking,
gender, antipsychotic medication, and dietary factors
does not explain the levels of membrane lipids [9, 26].
The notion that triglyceride levels may be a disease trait
is in accordance with recent findings of polygenic over-
lap between blood lipid levels and schizophrenia, sug-
gesting similar molecular genetic factors [41].
Higher levels of serum lipids were associated with
more severe psychiatric symptoms in the chronic phase
of the disease. We are not aware of similar findings.
Other studies have shown that an increase in serum
lipids is related to a reduction of symptoms among pa-
tients during treatment with antipsychotic medication
[28, 40]. Our findings may be due to more severely ill
patients having a more unhealthy lifestyle or being
treated with higher doses of antipsychotics, which both
can entail higher serum lipid levels. Earlier we have
shown that serum lipid levels were not significantly
higher among the patients using antipsychotic medica-
tion at T2 [26]. The present association between serum
lipids and symptoms and functioning became stronger
as the disease progressed to a more stable phase. This
may reflect increased oxidative stress during the acute
psychotic state, disrupting normal relationship between
serum lipids and psychiatric symptoms [42, 43]. Among
patients, triglyceride levels, and to a lesser degree chol-
esterol levels, at T1 were associated with symptom levels
at T2. Serum lipid levels seem to be related not only to
present symptoms, weight and medication, but also to
the disease itself. These findings may indicate that dis-
turbed serum lipid levels is a disease trait. This also
raises the possibility that serum lipids to some degree
may be used as a biomarker in schizophrenia.
To the best of our knowledge, the current study has
the longest follow-up period of membrane lipids (PUFA)
in schizophrenia yet reported. While long-term PUFA
levels in the healthy control group were stable, the levels
changed in the patient group. However, PUFA levels in-
creased only in the patients with low PUFA levels at T1,
while patients with higher PUFA had stable values. The
bimodal distribution of PUFA and LCPUFA reported
earlier at T1 [9] was not found at T2. Earlier reports on
the differences in PUFA levels have shown discrepancies.
Several studies have shown lower levels among patients
[9, 11] while others reported no such difference [37].
Meta-analyses have shown lower levels of LCPUFA in
schizophrenia patients than in healthy controls [10].
Lower levels of membrane lipids have been shown both
among drug-naïve patients and in patients treated with
antipsychotic drugs [38]. Discrepancies between studies
can reflect that PUFA levels were measured at different
stages during the course of the disease. During episodes
with higher symptom intensity, levels of membrane
lipids may be influenced by neuroinflammation, oxida-
tive stress and lipid peroxidation [44, 45]. Treatment
with atypical antipsychotic drugs may have a normaliz-
ing effect on the phospholipid composition of cell mem-
branes, especially for drug-naïve patients [38]. In the
present study, the PUFA levels in the chronic phase of
schizophrenia were not lower than in healthy controls,
possibly connected to long-term effects of antipsychotic
drugs on PUFA [4] or to the remission from an acute
psychotic episode [9].
Levels of membrane lipids (PUFA) were associated to
symptoms at the follow-up stage (T2) but not at the
acute stage (T1). At follow-up, higher levels of PUFA, es-
pecially LCPUFA, were associated with higher symptom
intensity and poorer functioning [26]. Our findings at T1
may reflect lipid peroxidation, to which LCPUFA, such
as DHA (docosahexaenoic acid) and EPA (eicosapenta-
enoic acid), are especially prone, and may support a role
of oxidative stress and free radicals in schizophrenia
[46]. Studies of fibroblasts from patients with schizo-
phrenia have shown decreased lysolipid levels and dis-
rupted extracellular matrix when exposed to oxidative
stress [47]. Antioxidant defenses are regulators of immuno-
logical pathways [16], Schizophrenia is among several
neuropsychiatric disorders for which neuroinflammatory
processes have been suggested to play a role [44, 48].
Markers of increased inflammation have been found in
post-mortem studies [49], in neuroimaging studies [50], in
cerebrospinal fluid [51] and peripherally in blood [52] from
schizophrenia patients, and disease severity has also been
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associated with inflammatory markers [53]. The relation-
ship between lipid metabolism and inflammation is estab-
lished through a series of experimental [54] and clinical
studies [55], including shared genetic risk [56]. There is a
link between inflammation and both serum lipids [57] and
membrane lipids [58]. Inflammation may affect lipid levels
through effects on arachidonic acid (ARA) and other phos-
pholipids [59, 60]. PUFA are not only important compo-
nents of neuronal cell membranes, but also play an
important role in regulation of inflammation through the
formation of eicosanoids [61]. Inflammation and oxidative
stress may play a role in disease progression through lipid
peroxidation and cholesterol oxidation, leading to neuronal
cell death [62, 63]. These mechanisms may change during
the course of the disease. This may explain the conflicting
findings regarding membrane lipids and symptoms in dif-
ferent stages of schizophrenia. The unstable character of
PUFA may explain why membrane lipids at T1 did not pre-
dict symptoms at T2, in contrast to serum lipids. Taken to-
gether, this indicates that, in contrast to serum lipids, the
levels of membrane lipids are associated with present
psychotic symptoms, and not future or past symptom
severity.
The current study has some limitations. T1 differ from
T2, both in terms of duration of illness and acute versus
chronic stage. Thus, the effect of duration of illness and
the stage may both explain why levels and correlations
differ between T1 and T2. The relative importance of
each of the characteristics and the influence of con-
founding factors may not be established by the present
design. The weight of the subjects was not obtained at
T2, and thus obesity as a factor connected to dyslipid-
emia cannot be adjusted for. However, it is unlikely that
weight affects the associations with symptom levels. Our
screening protocol ensured a very small likelihood that
any of the participants had familial dyslipidemia. How-
ever, diet, dietary supplements other than fatty acids,
and other lifestyle factors that may influence the lipid
levels, and family history of dyslipidemia were not con-
trolled for. Further, at T1 there were 16 different raters,
as opposed to one single rater at T2. More raters will
introduce statistical noise, weakening relationships be-
tween lipids and symptoms, which could explain lack of
association at T1. The control group was not matched
for smoking habits and other lifestyle factors, and not
for socioeconomic factors such as education level.
Though these parameters may influence the lipid levels,
matching them against a group of schizophrenia patients
would give a sample not representative of the general
population. The relative importance of disease and
medication cannot be clarified with the present design.
The design of the study is not fit to make conclusions
about causality. Since this is a naturalistic study, con-
founding factors not accounted for in the present
analysis can affect the lipid levels and clinical symptoms,
and the findings need to be replicated in independent
studies.
Conclusion
To conclude, serum lipid levels were elevated among pa-
tients both in the acute and chronic stage, while mem-
brane lipids were low in the acute phase of
schizophrenia. Serum lipid levels, both in the acute and
the chronic stages of schizophrenia, correlated with
chronic symptom levels, while membrane lipids showed
a more mixed relationship to symptom levels. These
findings suggest that higher serum lipids may be a dis-
ease trait of schizophrenia, and a possible biomarker,
and provide new insight into the role of lipid profiles in
schizophrenia pathophysiology.
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